Overview of Femiane

Property	Description
Active Ingredients	Ethinyl Estradiol and Gestodene
Form	Oral Coated Tablet (Monophasic)
Pharmacological Class	Combined Hormonal Contraceptive (CHC)
Common Use	Prevention of Pregnancy (Contraception)
Origin	Synthetic Preparation

Definition and Pharmacological Classification

Femiane is an oral contraceptive pill (OCP) formally classified as a Combined Hormonal Contraceptive (CHC). This places it within the high-level pharmacological grouping of steroid hormones used to modulate the genital system. The medicine is a synthetic preparation, meaning its active components are chemically manufactured rather than naturally sourced. The drug is prescribed specifically for women of reproductive age and is clinically recognized for its reliable efficacy in preventing conception.

Composition and Drug Form

The core of Femiane is its combination of two active pharmaceutical ingredients: the estrogen derivative Ethinyl Estradiol and the synthetic progestin Gestodene. Gestodene is recognized as a third-generation progestin, reflecting its chemical structure and development relative to earlier compounds. This signifies that the drug contains a modern, chemically advanced progestin component, which is a key differentiating factor in its pharmacological profile.

Femiane is supplied as a fixed-dose combination product in the form of an oral coated tablet. Every active tablet contains a constant quantity of both hormones, which defines it as a monophasic preparation. The constant daily hormone level is a feature that contributes to the consistent efficacy expected of this oral contraceptive.

General Purpose

The general and exclusive purpose of Femiane is to provide reliable contraception to prevent unintended pregnancy. Its primary role is to serve as a systemic method of hormonal control for individuals seeking effective, long-term pregnancy prevention, utilizing the convenience and consistent efficacy of the oral route of administration.

Regulatory References

National Library of Medicine

What side effects are possible with Femiane?

Possible Side Effects and Safety Information

The safety profile of combined hormonal contraceptives, including Femiane (a combination of ethinyl estradiol and gestodene), is based on clinical trial data and postmarketing surveillance.

Key Adverse Reactions

The most frequently reported adverse reactions from clinical trials generally relate to common side effects experienced with oral contraceptives. These typically include:

Nervous System and Psychiatric: Headache, migraine, and mood disorders.
Gastrointestinal: Nausea, vomiting, and abdominal pain/discomfort.
Reproductive and Breast: Breast tenderness or pain, vaginal candidiasis, and menstrual irregularities (such as spotting or bleeding between periods).
Other: Weight gain.

Serious and Clinically Significant Safety Concerns

Like all combined oral contraceptives, Femiane is associated with a risk of serious, though rare, adverse events, primarily related to the vascular system. Regulatory bodies require clear warnings regarding these risks:

Thromboembolic Events: Use is associated with an increased risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, and arterial thromboembolism, such as myocardial infarction (heart attack) and stroke. The risk of VTE is highest during the first year of use.
Vascular Problems: Use is contraindicated in individuals with a high risk of arterial or venous thrombotic diseases.
Malignancy: An increased risk of certain cancers, such as breast cancer and liver tumors (benign or malignant), has been reported in post-marketing experience with combined oral contraceptives.

Safety Monitoring and Restrictions

Specific safety-related restrictions and monitoring notes from official documents include:

Discontinuation for Surgery/Immobilization: The product must be stopped prior to major surgery or during prolonged immobilization due to the increased risk of VTE.
Discontinuation for Vascular Events: The product must be discontinued immediately if any thrombotic or thromboembolic event occurs.
Contraindications: Use is restricted in individuals with a history of VTE, unexplained abnormal uterine bleeding, known or suspected breast cancer or other estrogen- or progestin-sensitive cancers, and certain types of severe liver disease.

Users should be monitored for signs of VTE (e.g., severe leg pain, sudden shortness of breath) and arterial thrombosis, as well as significant changes in blood pressure or the occurrence of new or severe migraines.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents state that an overdose of Femiane, a combined hormonal contraceptive, is generally not likely to be life-threatening. However, seeking immediate professional medical attention is mandated in all overdose scenarios.

Documented Overdose Manifestations

The expected clinical manifestations following the ingestion of a dose larger than prescribed are typically mild. Regulator-documented signs and symptoms include nausea, vomiting, and subsequent withdrawal bleeding or vaginal bleeding that may occur several days later. In young female children before menarche, the only sign of overdose observed may be vaginal bleeding.

Required Emergency Actions

The most important action is to contact emergency medical services or a Poison Control Center immediately for evaluation. The management of overdose is purely symptomatic and supportive, as no specific antidote is known for this combination of hormones. Urgent medical attention is specifically required if an individual experiences symptoms suggestive of a serious complication associated with this class of medication, such as signs of a blood clot (e.g., unexplained shortness of breath or sudden severe chest pain).

Therapeutic Uses of Femiane

What Femiane Treats: Main Uses and Benefits

Femiane is commonly used to support effective prevention of pregnancy for women of reproductive age. The combined hormonal pill is also relevant in clinical settings for its supportive symptomatic benefits.

The medication is commonly used to help with symptomatic relief across several gynecological domains, including severe uterine cramping (dysmenorrhea), excessive menstrual blood loss (menorrhagia), symptoms related to Premenstrual Dysphoric Disorder (PMDD), and moderate acne vulgaris. This supportive use contributes to improved comfort during periods of heightened symptoms and may assist with managing symptoms that interfere with daily functioning and is relevant for easing cycle-related tension.

Quick Fact: Relief for Menstrual Symptom Burden

Femiane is commonly used to address clusters of symptoms that may become intense or disruptive, helping patients cope more steadily with difficult episodes. It also may assist with managing moderate acne vulgaris, helping to address symptoms related to hormonally driven skin changes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Femiane?

The eligibility for using Femiane (Ethinyl Estradiol and Gestodene) is strictly defined by regulatory documents, which approve its use for females of reproductive potential to prevent pregnancy. Use is prohibited or restricted in several populations.

Populations Who Must Not Use Femiane (Contraindications)

Femiane is contraindicated and must not be used in women with a current or history of venous or arterial thromboembolic events (e.g., DVT, PE, stroke, MI) or known hypercoagulopathies (e.g., Factor V Leiden) . Contraindications also include hormone-sensitive malignancy (e.g., breast cancer), severe hepatic disease, liver tumors, migraine with focal neurological symptoms, and undiagnosed abnormal genital bleeding.

Population-Specific Restrictions

Restriction Type	Regulatory Rule
Age and Lifestyle	Contraindicated in women over 35 years of age who smoke. Not indicated for use before menarche or in postmenopausal women.
Physiological Status	Contraindicated during confirmed or suspected pregnancy. Not recommended while breastfeeding or within 4 weeks postpartum.
Surgical Status	Must be discontinued at least 4 weeks before and 2 weeks after major surgery involving prolonged immobilization.

These rules define the required eligibility profile, ensuring the medicine is not used in populations where official documentation identifies an unacceptable health risk.

What should I know about interactions with other medicines?

The official regulatory profile for Femiane is defined by documented pharmacokinetic interactions that either increase the clearance of the contraceptive hormones or increase the exposure of co-administered medicines. The primary classification is Contraceptive Efficacy Antagonism when used with agents that induce the Cytochrome P450 (CYP) enzyme system.

Co-administration with potent CYP enzyme inducers, such as the antibiotic Rifampin or the herbal product St. John’s Wort (Hypericum Perforatum), significantly increases the metabolic clearance of Ethinyl Estradiol and Gestodene. This effect requires the use of additional non-hormonal contraception during co-treatment and for a specified time period afterward to protect against a reduction in effectiveness. Conversely, Ethinyl Estradiol inhibits certain CYP enzymes, leading to an increased serum exposure and potential alteration of clinical effects for co-administered drug substrates, including Tizanidine and Cyclosporine.

The highest severity classification involves specific Hepatitis C antiviral regimens (e.g., those containing Ombitasvir / Paritaprevir / Ritonavir), which are formally contraindicated in combination due to the risk of significant liver enzyme elevation (ALT). Official instructions also address Gastrointestinal Absorption Interference: if vomiting or diarrhoea occurs within four hours of administration, a protocol must be followed that includes continued pill-taking and the use of a non-hormonal backup method. These regulatory constraints structure the official interaction guidance.

Mechanism of Action

How Femiane Works

Central Neuroendocrine Feedback

The drug's primary action involves the synchronized activation of Estrogen and Progesterone Receptors in the brain's control centers. This triggers a negative feedback signal that suppresses the hormones necessary for egg maturation and release, resulting in anovulation (the inhibition of an egg being released from the ovary).

Local Tissue Modification

The progestin component acts locally on tissues in the reproductive tract to create important secondary physiological effects. It alters the cervical fluid, significantly increasing its viscosity, and induces an atrophic state in the uterine lining. These peripheral actions provide secondary mechanisms by impeding sperm mobility and reducing the lining's receptivity.

Systemic Hormone Regulation

The estrogen component modulates liver function to increase the production of Sex Hormone-Binding Globulin (SHBG). By binding to this carrier protein, the progestin component remains stable in the bloodstream, ensuring consistent receptor activation. This systemic regulation maintains the concentration thresholds required for consistent central suppressive signaling.

Dosage and Administration Information

Instruction Map: How to use Femiane — Official Administration Guidelines

Administration Scope

Category	Official Instruction
Route of administration	Oral
Dosing schedule	One active tablet daily for 21 consecutive days, followed by a 7-day hormone-free interval
Timing in relation to meals (if applicable)	Not specified as mandatory; tablets may be taken with or without food.
Age-group administration rules	Established for use in women of reproductive age; not indicated for use prior to menarche.
Special procedural conditions	The tablets must be taken daily at the same time and strictly in the sequential order designated on the blister pack.

Instruction Classifications (High-Level)

Classification	Pattern
Administration method type	Oral
Frequency pattern	Daily, continuous cyclic use
Regulatory basis	Prescribing information for the active combination.
Use-context constraints	Requires initiation of the regimen on either Day 1 (first day of menses) or the Sunday following the start of menses.

Connection to the Overall Use Protocol

The combined official instructions establish a fixed daily oral administration protocol organized into a 28-day continuous cyclic pattern. This structure mandates procedural compliance, requiring specific tablet sequencing and consistent daily timing to ensure the regimen is executed precisely as documented in established guidelines. The protocol is designed for long-term use and dictates both the initiation methods and the required daily maintenance actions.

Recent Clinical Evidence

Research evidence / Overview of studies for Femiane

Evidence for Use in Pregnancy Prevention (Contraception)

The research base for Femiane and the wider class of Combined Hormonal Contraceptives (CHCs) primarily consists of large-scale observational studies and controlled trials that research examined over several decades. These studies focused on healthy women of reproductive age who were seeking contraception. Trials was studied for how frequently pregnancies occurred, measured by the Pearl Index (the number of pregnancies reported per 100 women over one year of use).

Studies also included specialized pharmacokinetic (PK) trials which studies monitored the levels of ethinyl estradiol and gestodene in the bloodstream. Findings describe patterns observed in the studies that show hormone levels that were observed to be consistent with the physiological processes explored in ovulation inhibition studies. Overall, the research landscape for contraceptive efficacy across the entire CHC class is extensive, and this specific formulation was evaluated in studies intended to evaluate its profile relative to other hormonal contraceptives.

Evidence for Supportive Uses (Menstrual Symptoms and Acne)

Research has explored the use of combined pills for conditions characterized by fluctuating or episodic manifestations, particularly related to the menstrual cycle. Randomized Controlled Trials (RCTs) was studied for outcomes related to physical discomfort like severe menstrual cramping (dysmenorrhea) and outcomes linked to inflammatory or irritative states like moderate acne vulgaris. Research also examined conditions involving periods of heightened symptoms, such as excessive menstrual bleeding (menorrhagia).

Studies used patient-reported outcomes to measure changes in pain intensity scores and documented measured requirements for rescue pain medication. For heavy bleeding, researchers monitored and reported assessments of changes in the amount of menstrual blood loss. For acne, trials studied monitored changes in lesion counts and acne severity scores over periods lasting up to a year.

What is Still Uncertain About the Research

One key research limitation is that direct, head-to-head comparative evidence is often lacking for the supportive uses (like acne or dysmenorrhea) between the specific third-generation progestin in Femiane (gestodene) and all other progestin types in the same pill class. Findings were mixed in comparing different formulations for these outcomes, making it difficult to distinguish the relative findings of this pill versus a different combined pill. Additionally, researchers consistently note that while short-term changes are well-documented, long-term effects are not fully established for many of the supportive, non-contraceptive benefits.

Key Studies & References

Acne clinical guideline - American Academy of Dermatology (AAD) recommendations for COCs

Frequently Asked Questions (FAQ)

Common questions about Femiane (FAQ)

Q: Is Femiane a birth control pill, or does it treat something else?

A: Femiane is officially classified as a Combined Hormonal Contraceptive (CHC), and its primary purpose is the prevention of pregnancy. Studies and official information also indicate it has supportive uses. Research has examined its use in managing conditions such as dysmenorrhea (painful periods) and moderate acne vulgaris.

Q: Why are there two different types of pills in the Femiane pack?

A: The medicine pack is part of a continuous cyclic administration protocol defined in official documents. It contains 21 active tablets that deliver hormones and tablets for the 7-day hormone-free interval. This cycle structure reflects the daily administration protocol described in official product information.

Q: Do the side effects of Femiane usually go away after a few months?

A: Official information indicates that common side effects, such as spotting or breakthrough bleeding (unscheduled bleeding), often improve or resolve over time. These issues have been noted in studies to improve or resolve, often within the initial adjustment period.

Q: Does taking Femiane affect my mood or emotional state?

A: Yes, official safety information lists mood disorders among the adverse reactions that have been reported from clinical trial data. These reactions relate to the nervous system and psychiatric health observed in individuals using the medicine.

Q: Can Femiane cause changes to my skin or hair?

A: Adverse reactions related to skin or hair have been documented in official product profiles. These have included issues such as acne and changes in body or head hair growth, such as hair loss or an increase in hair.

Q: What common herbal supplements or vitamins might interact with Femiane?

A: Official regulatory documents specifically address a risk of reduced effectiveness when the medicine is co-administered with the herbal product St. John’s Wort (Hypericum Perforatum). This interaction may reduce the effectiveness of Femiane.

Q: How quickly does Femiane start working for its intended purpose?

A: When the medicine is started on the first day of the menstrual cycle, official protocol indicates that contraceptive protection begins immediately. If initiation occurs on days 2–5, or later, official protocols indicate that additional non-hormonal protection may be required for the first 7 consecutive days.

Q: If I stop taking Femiane, how long does it take for the effects to wear off?

A: Studies on combined hormonal contraceptives generally indicate a quick return to the body's natural hormonal function after discontinuation. Fertility has been noted in studies to return within the first few menstrual cycles following discontinuation.

Q: How long can a person safely use Femiane?

A: Femiane is generally designed for long-term use in women of reproductive age seeking contraception. However, official restrictions apply based on risk factors, notably for women over 35 years of age combined with smoking.

Q: Can Femiane affect fertility after a person stops taking it?

A: No, official data indicates that stopping the medicine is not generally associated with long-term changes to a person’s ability to conceive. Research indicates that the return to fertility after stopping is comparable to baseline rates observed in women not using hormonal contraception.

Q: Where can I find official information or patient leaflets about Femiane?

A: Official information is maintained by government bodies and is available through national health resources. This information can be found in documents such as the Summary of Product Characteristics (SmPC) or the prescribing information provided by national regulatory agencies.

Q: What happens if I miss a pill when taking Femiane?

A: Official protocol addresses situations where the daily tablet is taken outside of the designated time window. Contraceptive protection is maintained if the tablet is taken less than 12 hours late. If the delay is more than 12 hours, effectiveness may be reduced, and the specific protocol defined in official documents includes using non-hormonal contraception for a period of 7 days.

Q: Does Femiane cause spotting or breakthrough bleeding?

A: Yes, official safety information lists spotting or bleeding between periods as a common menstrual irregularity. This unscheduled bleeding is commonly referred to by users as breakthrough bleeding.

Q: Is it normal to have a very light period, or no period, while on Femiane?

A: Due to the hormonal effects on the uterine lining, some users may find their withdrawal bleed during the hormone-free interval is lighter than usual. The absence of a bleed, known as amenorrhea, has been noted to occur.

Q: Do I need to use another form of protection when I first start Femiane?

A: Official initiation guidelines indicate that if the tablets are started on days 2–5 of the menstrual cycle, or if the start is delayed in certain medical contexts, official protocols indicate that additional non-hormonal contraception may be required for the first 7 consecutive days.

Q: Can vomiting or severe diarrhea reduce the effectiveness of Femiane?

A: Yes, regulatory information states that if vomiting or diarrhoea occurs within four hours of taking an active tablet, the absorption of hormones may be compromised. Official protocol addresses this scenario, including the recommendation to use a non-hormonal backup method.

Q: Is Femiane still effective if I take it a few hours late?

A: Official information indicates that contraceptive protection is maintained if an active tablet is taken less than 12 hours after the scheduled time. However, a delay of more than 12 hours may reduce the medicine's effectiveness.

Q: Does Femiane change the nature of my menstrual cycle?

A: Use of this medicine is associated with changes to the menstrual pattern. This includes the potential for menstrual irregularities and studied reductions in symptoms such as dysmenorrhea (cramping) and the amount of menstrual blood loss.

Q: What should I do if I experience headaches on Femiane?

A: While headaches are listed as an adverse reaction, official guidance states that the medicine should be immediately discontinued and evaluated if new or severe migraines occur. This is especially true if the migraines are associated with focal neurological symptoms.

Q: Is it necessary to have a 'withdrawal bleed' every month on Femiane?

A: The standard regimen includes a 7-day hormone-free interval to induce a withdrawal bleed. However, official information indicates that experiencing a bleed is not required for the medicine's function, and the absence of a bleed has been noted to occur.

Q: What is the difference between the active and inactive pills in the pack?

A: The active tablets contain the two hormones, ethinyl estradiol and gestodene, and are taken for 21 days. The tablets taken during the 7-day hormone-free interval do not contain any hormones.

Q: What are the signs of a serious side effect related to taking Femiane?

A: Official safety monitoring requires awareness of signs related to serious vascular events. These include symptoms of venous thromboembolism (VTE), which can involve severe leg pain or sudden shortness of breath, and signs of arterial thrombosis.

Q: Can taking Femiane make my existing migraines worse?

A: The product is officially contraindicated in women with migraine with focal neurological symptoms. Official guidance states that the occurrence of any new or severe migraines requires immediate discontinuation and evaluation.

How should Femiane be stored and disposed of?

How to Store and Dispose of Femiane

The storage and disposal of Femiane must adhere strictly to the conditions specified in official regulatory documents to maintain the medicine’s integrity and stability.

Storage Requirements

The tablets must be stored at a temperature that does not exceed 25°C and must be protected from light. The medicine has an official shelf-life of 5 years when kept in its original packaging (blister strips) under these conditions. As a general safety precaution, the product must be stored out of the sight and reach of children.

Disposal Instructions

Official product labeling states no special requirements for disposal. Unused or expired tablets should therefore be handled according to general regulatory guidelines. This typically involves using a drug take-back program or safely disposing of the medicine in the household trash after mixing it with an undesirable substance and sealing it in a container.

Femiane